Access of the substrate to the active site of squalene and oxidosqualene cyclases: comparative inhibition, site-directed mutagenesis and homology-modelling studies.

Substrate access to the active-site cavity of squalene-hopene cyclase from Alicyclobacillus acidocaldarious and lanosterol synthase [OSC (oxidosqualene cyclase)] from Saccharomyces cerevisiae was studied by an inhibition, mutagenesis and homology-modelling approach. Crystal structure and homology modelling indicate that both enzymes possess a narrow constriction that separates an entrance lipophilic channel from the active-site cavity. The role of the constriction as a mobile gate that permits substrate passage was investigated by experiments in which critically located Cys residues, either present in native protein or inserted by site-directed mutagenesis, were labelled with specifically designed thiol-reacting molecules. Some amino acid residues of the yeast enzyme, selected on the basis of sequence alignment and a homology model, were individually replaced by residues bearing side chains of different lengths, charges or hydrophobicities. In some of these mutants, substitution severely reduced enzymatic activity and thermal stability. Homology modelling revealed that in these mutants some critical stabilizing interactions could no longer occur. The possible critical role of entrance channel and constriction in specific substrate recognition by eukaryotic OSC is discussed.

[1]  F. Viola,et al.  3-carboxy-4-nitrophenyl-dithio-1,1′,2-trisnorsqualene: A site-directed inactivator of yeast oxidosqualene cyclase , 1993, Lipids.

[2]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[3]  T. Schulz-Gasch,et al.  Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase , 2004, Nature.

[4]  G. Schulz,et al.  Conversion of squalene to the pentacarbocyclic hopene. , 2004, Chemistry & biology.

[5]  O. Morand,et al.  Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors. , 2003, Journal of medicinal chemistry.

[6]  G. Schulz,et al.  Binding structures and potencies of oxidosqualene cyclase inhibitors with the homologous squalene-hopene cyclase. , 2003, Journal of medicinal chemistry.

[7]  Martin Stahl,et al.  Mechanistic insights into oxidosqualene cyclizations through homology modeling , 2003, J. Comput. Chem..

[8]  G. Schulz,et al.  Thiol-modifying inhibitors for understanding squalene cyclase function. , 2002, European journal of biochemistry.

[9]  G. Schulz,et al.  Enzyme Mechanisms for Polycyclic Triterpene Formation. , 2000, Angewandte Chemie.

[10]  G. Schulz,et al.  The structure of the membrane protein squalene-hopene cyclase at 2.0 A resolution. , 1999, Journal of molecular biology.

[11]  G. Schulz,et al.  Structure and function of a squalene cyclase. , 1997, Science.

[12]  O. Morand,et al.  Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. , 1997, Journal of lipid research.

[13]  J. Griffin,et al.  Isolation and characterization of the gene encoding 2,3-oxidosqualene-lanosterol cyclase from Saccharomyces cerevisiae. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Corey,et al.  Molecular cloning, characterization, and overexpression of ERG7, the Saccharomyces cerevisiae gene encoding lanosterol synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  I. Abe,et al.  Enzymic cyclization of 2,3-dihydrosqualene and squalene 2,3-epoxide by squalene cyclases: from pentacyclic to tetracyclic triterpenes , 1994 .

[16]  G. Prestwich,et al.  ENZYMATIC CYCLIZATION OF SQUALENE AND OXIDOSQUALENE TO STEROLS AND TRITERPENES , 1993 .

[17]  R. Woodward,et al.  THE CYCLIZATION OF SQUALENE IN CHOLESTEROL SYNTHESIS , 1953 .